In any due diligence process, knowing the assumptions that drive the value estimate and the methodology used to balance anticipated investments, risks, and rewards will allow for a company to adjust the diligence review accordingly. This discussion will cover:
- Approaches for developing valuation and valuation assumptions for in-licensing, M&A, IPO, and R&D
- Evaluating the future impact of key items when reviewing a biotech IP portfolio
- Identifying factors that executives use to arrive at a starting value, and then quantifying the deductions depending on the results of the IP due diligence
- Valuation methodologies used for early-stage vs. late-stage products
Panelists include: Gregg Alton, Senior Vice President and General Counsel, Gilead Sciences, Inc.; Doug Crawford, Associate Executive Director, QB3; Doug Sheehy, Vice President & General Counsel, Codexis, Inc.; and Paul Stewart, Partner, Foley.
Related Insights
23 December 2024
Labor & Employment Law Perspectives
Regulating Artificial Intelligence in Employment Decision-Making: What’s on the Horizon for 2025
Share on TwitterShare by EmailShareBack to topEmployment law in 2024 could aptly be summarized as the “Year of Artificial Intelligence Legislation.
23 December 2024
Injunction Stayed: Corporate Transparency Act Enforcement Resumes
The U.S. Department of Justice scored a victory in ongoing litigation over the constitutionality of the Corporate Transparency Act (CTA) when the Fifth Circuit Court of Appeals stayed the nationwide preliminary injunction issued earlier this month by a federal district court in Texas.
23 December 2024
Health Care Law Today
Medicare Telehealth Flexibilities Get a Three-Month Lifeline
Share on TwitterShare by EmailShareBack to topAfter much uncertainty, Congress has extended many Medicare telehealth flexibilities through March 31, 2025, in its end-of-year appropriations bill.